
Pfizer NYSE: PFE expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies London Healthcare Conference.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
| Revenue (TTM) | $63.62B |
| Gross Profit (TTM) | $47.65B |
| EBITDA | $24.94B |
| Operating Margin | 29.10% |
| Return on Equity | 4.47% |
| Return on Assets | 5.59% |
| Revenue/Share (TTM) | $11.17 |
| Book Value | $15.61 |
| Price-to-Book | 1.85 |
| Price-to-Sales (TTM) | 2.59 |
| EV/Revenue | 3.349 |
| EV/EBITDA | 15.82 |
| Quarterly Earnings Growth (YoY) | -9.70% |
| Quarterly Revenue Growth (YoY) | -0.40% |
| Shares Outstanding | $5.70B |
| Float | $5.69B |
| % Insiders | 0.26% |
| % Institutions | 69.27% |
Volatility is currently expanding

Pfizer NYSE: PFE expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies London Healthcare Conference.

Investors are downbeat on Pfizer, at least in part due to concerns about innovation and patent expirations. The company continues to invest in new drugs, but innovation can't be scheduled.

PFE shares fell despite the company beating Q3 estimates and raising guidance. Explore its growth drivers, pipeline potential, patent risks & attractive valuation.

Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity. PFE faces stagnant revenues, heavy debt, and looming patent expiries on key drugs, making GLP-1 success critical for future growth. Berobenatide offers monthly dosing and potential manufacturing cost advantages, but safety and efficacy data have notable gaps versus established competitors.

PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.

Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.

The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will.

Pfizer's recently launched and acquired products have been generating impressive growth. The stock is up big this year, but its valuation remains modest based on analyst expectations.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PFE and any ticker you trade — then tracks every position and per-strategy win rate.